Most pages in this cluster have to explain why no authoritative dose figure exists. Oxytocin has one, published in a current FDA label, updated in 2026, with precise numbers throughout.
It is still not the number anybody is looking for, and the gap between what the label says and what the market discusses is the largest of any compound on this site.
What the label states
The PITOCIN label (Par Health USA, DailyMed set id 6e5a66fc-e507-497c-b5ce-44a8c95898ad, published 21 May 2026) begins its dosage section with a sentence that shapes everything after it: the dosage of oxytocin is determined by the uterine response and must therefore be individualised and initiated at a very low level.
Induction or stimulation of labor. The label states that intravenous infusion by the drip method is the only acceptable method of parenteral administration for this indication. The standard solution is one 1 mL vial containing 10 units added to 1,000 mL of 0.9% sodium chloride or Ringer's lactate — a concentration of 10 milliunits per mL.
| Stage | What the label specifies |
|---|---|
| Starting rate | 0.5–1 milliunit/minute (3–6 mL/hour of the dilute solution) |
| Increment | 1–2 milliunits/minute, at 30–60 minute intervals |
| Endpoint | The desired contraction pattern; then reduced by similar increments once labor reaches 5–6 cm dilation |
| Physiological reference | Rates up to 6 milliunits/minute give the same maternal plasma levels found in spontaneous labor |
| Practical ceiling | Rates exceeding 9–10 milliunits/minute are rarely required at term |
Control of postpartum uterine bleeding. 10 to 40 units added to a running intravenous infusion, to a maximum of 40 units per 1,000 mL, with the rate adjusted to sustain uterine contraction; or 10 units intramuscularly after delivery of the placenta.
Incomplete, inevitable or elective abortion. 10 units added to 500 mL of physiologic saline or 5% dextrose.
The label also carries an IMPORTANT NOTICE inside its indications section stating that Pitocin is not indicated for elective induction of labor, because the available data are inadequate to evaluate the benefits-to-risks considerations.
These figures are reported here as what the label states. Nothing on this page is a recommendation, and decisions about administering anything to a person belong with a clinician.
The first mismatch: a dose per minute, against a watched endpoint
Almost every other entry in this catalogue can be reduced to a quantity and an interval — so many milligrams, so many times a week. Oxytocin cannot, and the reason is written into the label.
The labelled instruction is a titration procedure, not a quantity. It starts below the level expected to do anything, rises in small steps at fixed intervals, and stops rising when a contraction pattern appears on a monitor. The label pairs this with the instruction that the infusion can be stopped abruptly, and that uterine stimulation will soon wane when it is. The whole design assumes continuous observation and an immediate off switch.
This is worth stating plainly because it is the honest answer to "what is the oxytocin dose": there is no such number in the approved record. There is a starting rate, a step size, a physiological reference point, and a ceiling that is described as rarely necessary rather than as a maximum. On this site's six-tier grading of dose claims, this is a tier-1 source that declines to state a tier-1 figure.
The second mismatch: the route
The non-obstetric conversation about oxytocin — the one that drives the search volume — is almost entirely about intranasal administration. That is not an alternative presentation of the approved product. It is a formulation with no approved US product behind it.
We queried DailyMed for oxytocin on 19 September 2026 and classified all 41 records:
| Kind of record | Count |
|---|---|
| Injection records (human and veterinary) | 23 |
| Bulk active-ingredient powders | 2 |
| Multi-ingredient non-injection preparations (homeopathic oral liquids, drops, sprays) | 16 |
| Intranasal prescription oxytocin products | 0 |
An openFDA route census for the same substance on the same date corroborates it from a second direction: ORAL 16, INTRAVENOUS 10, INTRAMUSCULAR 6. No nasal route is recorded for oxytocin at all. The two records whose titles contain the word spray are multi-ingredient homeopathic weight-loss formulas.
Meanwhile ClinicalTrials.gov returns 290 registrations mentioning intranasal oxytocin, against 1,399 mentioning oxytocin in any form. So roughly one registered oxytocin study in five administers a formulation that has no approved product in the United States, and that entire body of work is the source of every figure the research market quotes.
What the intranasal trials actually used, which is not one number either
We took the first 40 of those 290 registrations and extracted every dose figure stated in international units from their intervention descriptions. There were 62 of them.
| Dose | Mentions |
|---|---|
| 24 IU | 21 |
| 40 IU | 9 |
| 4 IU | 5 |
| 8 IU | 4 |
| 32 IU | 3 |
| 48 IU | 3 |
| Others (0.125, 2.4, 6, 10, 16, 20 IU) | 14 |
24 IU is the single most common figure and appears in about a third of the dose statements. It is also the figure that has propagated into every retail page on the subject. The rest of the distribution is what makes it a convention rather than a result: the same body of work has administered doses spanning from 0.125 IU to 48 IU, a range of nearly 400-fold, without a dose-finding programme converging on any of them.
That is the honest description of the number: a widely repeated protocol convention in a research literature that has not established a dose, administered by a route with no approved product, for indications no regulator has approved.
The unit problem, again
Oxytocin is dosed in USP Units. A USP Unit is a potency measure defined against a reference standard, not a mass — the same class of unit as an insulin unit, and the same problem documented on chorionic gonadotropin. Converting to milligrams requires a potency-to-mass relationship for the specific preparation, which the vial supplies and the literature generally does not.
This is why oxytocin sits in the small group of entries that cannot be placed alongside the milligram-denominated compounds on the peptide dosage chart without a conversion nobody has supplied. It is not a gap in the chart; it is a property of the compound.
Where oxytocin sits in this catalogue
It is a nine-amino-acid cyclic peptide — smaller than almost anything else here, and genuinely a peptide, unlike several entries that are catalogued because they are sold through the same channels. It has a real label with real numbers, which puts it in the company of semaglutide, tirzepatide, bremelanotide, elamipretide and chorionic gonadotropin.
And it is the clearest case in the catalogue of a compound where having an approved label answers none of the questions being asked of it. The label's route is an intravenous drip; the market's route is a nasal spray with no approved product. The label's unit is a potency measure; the market wants milligrams. The label's dose is a titration against a monitored contraction pattern; the market wants a number. All three gaps are properties of the approved record, not omissions from it.
The route question raised here is general, and oxytocin is its sharpest example.
Sources
- PITOCIN (oxytocin) injection label, Par Health USA, LLC. DailyMed set id
6e5a66fc-e507-497c-b5ce-44a8c95898ad, published 21 May 2026. Dosage and Administration, Indications and Usage, Contraindications. Read 19 September 2026. - DailyMed SPL query, drug name "oxytocin", 41 records, classified by dosage form. Read 19 September 2026.
- openFDA drug label API, route census for substance name OXYTOCIN. Read 19 September 2026.
- ClinicalTrials.gov API v2, term queries "oxytocin" (1,399) and "intranasal oxytocin" (290), with dose extraction from the first 40 intranasal records' intervention descriptions. Read 19 September 2026.